Pharmaceutical firms aim for growth in anti-cancer drugs

International pharmaceutical companies are investing heavily in their presence at the second China International Import Expo in Shanghai, from 5 to 10 November. The focus of their presence, with large 700/800 sqm booths, is to launch more anti-cancer drugs to the Chinese market.

Among the pharmaceutical companies are Pfizer Biopharmaceuticals Group, Roche Pharmaceuticals, Merck Sharp & Dohme and Johnson & Johnson.

Shanghai Daily reports that Pfizer China Biopharma will introduce several medicines including Ibrance used by advanced-stage breast cancer patients. The company has invested over US$1.5 billion in China, setting up four advanced production facilities and two research and development centers.

Roche Pharmaceuticals China will present new products and the latest technology in the fields of breast cancer, influenza and cancer immunotherapy. The company was the first transnational pharmaceutical company to build a fully owned R&D center in Shanghai.

MSD will showcase drugs, vaccines and animal health products and services that it hopes will support the country’s ‘Healthy China 2030’ plan.

Further reading on

< Previous Next >

Related articles